NCT04683185 is a Phase 1 clinical trial of E6742 in Healthy Volunteers, sponsored by Eisai Co., Ltd..

Who is sponsoring NCT04683185?

NCT04683185 is sponsored by Eisai Co., Ltd..

What drugs are being tested in NCT04683185?

Interventions in NCT04683185: E6742, Placebo.

What condition does NCT04683185 study?

NCT04683185 studies Healthy Volunteers.

Is NCT04683185 still recruiting?

NCT04683185 is currently completed. Last updated 20 July 2021.

Last reviewed 2021-07-20 · How we verify

NCT04683185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

Completed Phase 1 Last updated 20 July 2021

What this trial tests

Phase 1 trial testing E6742 in Healthy Volunteers in 24 participants. Completed in 21 June 2021.

Timeline

28 December 2020

Primary endpoint
21 June 2021

21 June 2021

Quick facts

Lead sponsor	Eisai Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	24
Start date	28 December 2020
Primary completion	21 June 2021
Estimated completion	21 June 2021
Sites	1 location across Japan

Drugs / interventions tested

E6742 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

Adults 20 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending oral doses of E6742 in Japanese healthy adult participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration.
Tanaka Y, Tago F, Yamakawa N, Aoki M, et al · · 2024 · cited 8× · PMID 37772762 · DOI 10.1080/25785826.2023.2264023

Verify or expand the search:

Other trials of E6742

Trials testing the same drug.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT05278663 — A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants · Phase 1, PHASE2 · completed
NCT03082235 — Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04683185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 20 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04683185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing